Search for a trial

The development of a thirst provocation test using the AVP receptor antagonist Tolvaptan for quantification of thirst sensation in various patient groups (obese patients with and without a history of bariatric surgery, patients with congestive heart failure and patients with cranial diabetes insipidus as compared to healthy controls) and genotyping of the AVP receptor 2.

We aim to investigate thirst in the above mentioned patient groups, applying a Visual Analogue Scale (VAS) and, where ethically acceptable, a new thirst provocation test which we will develop in a group of healthy probands. Using these tools, we aim…

Can HDL Infusions Significantly Quicken Atherosclerosis Regression?
A phase II, Multi-center, double-blind, ascending dose, placebo-controlled, dose-finding trial of CER-001 or placebo in subjects with acute coronary syndrome.

To assess the impact of six IV infusions of 3, 6, or 12 mg/kg of CER-001 or placebo, given at weekly intervals, on atherosclerotic plaque volume, as measured by coronary IVUS.

Perioperative esmolol infusion for haemodynamic stability during major vascular surgery.

Primary Objective: comparing hemodynamic stability provided by titration of esmolol in addition to standard perioperative care including low-dose metoprolol to placebo and standard care.Secondary Objective(s): -comparing the incidence of…

The influence of sunitinib on contractility of human atrial trabeculae

The primary objective of the study is to investigate the effect of sunitinib on ex-vivo atrial contractile force in absence and presence of ischemia-reperfusion. A secondary objective is to explore if atorvastatin or AICAR prevent sunitinib-induced…

Does ticagrelor modulate the inflammatory respons to human endotoxemia?

To study whether ticagrelor, added to acetylsalicylic acid, modulates the inflammatory response to the administration of lipopolysaccharide (LPS) in humans in vivo.

An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention.

Dual Primary Objectives:* To determine if apixaban is noninferior to VKA (INR target range 2.0-3.0) on the combined endpoint of ISTHmajor or clinically relevant non-major bleeding in patients with NVAF who develop ACS or undergo PCI withplanned…

Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia;The RAPID Study (NODE-301 Part 2)

The primary objective of the RAPID study is to determine whether etripamil nasal spray (NS) self-administered by patients is superior to placebo at terminating episodes of PSVT in an at-home setting.The secondary objective of this study is to…

A study evaluating the pharmacokinetics, safety and tolerability of OP2113 administered intravenously in healthy volunteers and a marketed formulation administered orally

Primary objectives1. To evaluate the pharmacokinetic (PK) profile of the parent compound (anethole trithione, ATT) and its main metabolite (5-[4-hydroxyphenyl]-3H-1,2-dithiole-3-thione, ATX ) following administration of a range of doses of i.v.…

Specifying the anti-inflammatory effects of ziltivekimab with diverse imaging modalities and in-depth cellular phenotyping

This study has been transitioned to CTIS with ID 2024-515893-29-01 check the CTIS register for the current data. To study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory…

Brain Outcome after Cardiac Arrest
Modifying working memory with non-invasive brain stimulation - A series of SCEDs

Aim of the studyThis is a proof-of-concept study to investigate the effects of rTMS (iTBS protocol) on working memory of people with memory impairments after a cardiac arrest in the past. We propose a series of single case experimental design (SCED…